MORF (Morphic Holding Inc) Forward P/E Multiple

Corporate emblem and logo of Morphic Holding, Inc. (MORF)

The forward P/E ratio of Morphic Holding, Inc. (MORF) reflects market expectations, with the current value standing at 0.00. This trend is driven by the company's ownership of patents for unique gastrointestinal pills, which limits the expansion of industry behemoths. Scientific management is aggressively promoting an innovative platform through clinics. This process is supported by robotic screening stations and software for the automated analysis of medical data sets.

MORF - Morphic Therapeutic Market Cap to Projected Earnings over the range 07/04/2022 - 08/24/2024

Metric breakdowns and analytics for Morphic Holding Corp (MORF)

- current price and projected stock value:
Stock Quotes Morphic|MORF - Fair Value Consensus
- business market valuation indicators:
Market Capitalization Morphic Holding, Inc.|MORF - Full Takeover Company Value
- book capitalization information:
Book Value per Share Morphic|MORF - Book Valuation of Business|Market Cap to Net Assets Ratio morphictx.com|MORF - Aggregate Business Assets
- debt and liquidity data:
Debt to Equity Morphic Holding, Inc.|MORF - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Morphic Holding, Inc.|MORF - Company Cumulative Debt|Debt to Book Capitalization Ratio Morphic Holding, Inc.|MORF - Company Long-Term Loans and Borrowings|Company Short-Term Debt Morphic|Quick Ratio morphictx.com
- earnings and market ratios statistics:
MORF - Final Profit|Projected Future Earnings Morphic Holding, Inc.|MORF - Business Payback Period|Forward P/E Multiple Morphic Holding Inc|MORF - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio Morphic Holding, Inc.|MORF - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Morphic|MORF - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months morphictx.com|MORF - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Morphic Holding, Inc.
- revenue and sales proceeds data:
MORF - Company Revenue|Projected Sales Volume Morphic|MORF - Market Cap to Revenue Ratio
Analysis of all company metrics:MORF Morphic
Signature product of Morphic Holding, Inc.

When constructing a defensive portfolio, fundamental screening requires distinguishing between undervaluation and business degradation by analyzing the ratio of current price to projected earnings per share. For Morphic Holding, Inc. (MORF), whose US developments are protected by the humanitarian status of medicine, the company's forward P/E serves as an entry point indicator when market skepticism shifts toward recognizing the stability of the clinical cycle.

Direct competitors

Projected Price to Earnings PHAT (Phathom Pharmaceuticals, Inc.)|TERN (Terns Pharma) - Future Price to Earnings Multiple|Forward P/E Multiple IRWD (Ironwood Pharmaceuticals, Inc.)|Forward Price to Earnings Multiple Curanex Pharma|Immuron Inc - Forward P/E Multiple|Market Cap to Projected Earnings evokepharma.com EVOK|ENTO (enterothera.com) - Projected Price to Earnings|RDHL: Market Cap to Future Earnings Ratio|Future Price to Earnings Palisade Bio, Inc.|Projected Price to Earnings Jaguar Health Corp (JAGX)|Future Price to Earnings Biora Therapeutics (BIOR)